We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $2.04B
1-Year Est. Return 94.26%
This Fund
S&P 500
This Quarter Est. Return
+21.35%
1 Year Est. Return
+94.26%
3 Year Est. Return
+310.51%
5 Year Est. Return
+306.13%
10 Year Est. Return
+3,783.92%
AUM
$2.04B
AUM Growth
+$120M
Cap. Flow
-$149M
Cap. Flow %
-7.33%
Top 10 Hldgs %
47.27%
Holding
257
New
21
Increased
32
Reduced
47
Closed
104

Top Buys

Rank Stock Value
1
U icon
Unity
U
+$16.4M
2
TRAX
First Tracks Biotherapeutics
TRAX
+$14M
3
SE icon
Sea Limited
SE
+$11.9M
4
NU icon
Nu Holdings
NU
+$10.1M
5
GOSS icon
Gossamer Bio
GOSS
+$9.54M

Top Sells

Rank Stock Value
1
ASTH icon
Astrana Health
ASTH
+$17.6M
2
LLY icon
Eli Lilly
LLY
+$15.3M
3
GXO icon
GXO Logistics
GXO
+$14.8M
4
FOLD
Amicus Therapeutics
FOLD
+$11.2M
5
APLS
Apellis Pharmaceuticals
APLS
+$10.1M

Sector Composition

Rank Sector Weight
1 Miscellaneous 48.9%
2 Healthcare 24.5%
3 Financials 7.3%
4 Consumer Discretionary 7.28%
5 Technology 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DIBS icon
176
1stdibs.com
DIBS
$152M
– –
-175,786
Closed -$967K
DUOT icon
177
Duos Technologies
DUOT
$277M
– –
-106,481
Closed -$730K
ELTX icon
178
Elicio Therapeutics
ELTX
$57.3M
– –
-56,442
Closed -$603K
FBRX
179
DELISTED
Forte Biosciences
FBRX
– –
-20,000
Closed -$518K
FCEL icon
180
FuelCell Energy
FCEL
$1.32B
– –
-85,110
Closed -$556K
FOLD
181
DELISTED
Amicus Therapeutics
FOLD
– –
-775,000
Closed -$11.2M
FOSL icon
182
Fossil Group
FOSL
$287M
– –
-175,000
Closed -$754K
GALT icon
183
Galectin Therapeutics
GALT
$408M
– –
-162,484
Closed -$453K
GEOS icon
184
Geospace Technologies
GEOS
$67M
– –
-39,252
Closed -$479K
GNLX icon
185
Genelux
GNLX
$114M
– –
-60,000
Closed -$145K
GSAT icon
186
Globalstar
GSAT
$10.6B
– –
-98,000
Closed -$6.51M
GSIT icon
187
GSI Technology
GSIT
$215M
– –
-118,835
Closed -$611K
HYMC icon
188
Hycroft Mining Holding Corp
HYMC
$2.13B
– –
-15,000
Closed -$528K
IDN icon
189
Intellicheck
IDN
$53.7M
– –
-70,000
Closed -$489K
IMRX icon
190
Immuneering
IMRX
$298M
– –
-150,697
Closed -$794K
INFU icon
191
InfuSystem Holdings
INFU
$243M
– –
-100,465
Closed -$927K
INO icon
192
Inovio Pharmaceuticals
INO
$136M
– –
-248,790
Closed -$433K
IRS
193
IRSA Inversiones y Representaciones
IRS
$1.31B
– –
-70,000
Closed -$1.13M
IA
194
Innovative Solutions & Support
IA
$324M
– –
-18,000
Closed -$370K
DFDV
195
DeFi Development Corp
DFDV
$177M
– –
-30,000
Closed -$98.7K
LEN.B icon
196
Lennar Class B
LEN.B
$19.1B
– –
-115,000
Closed -$9.67M
LLY icon
197
Eli Lilly
LLY
$1T
– –
-15,000
Closed -$15.3M
LODE icon
198
Comstock
LODE
$231M
– –
-220,000
Closed -$671K
LPTH icon
199
Lightpath Technologies
LPTH
$637M
– –
-65,000
Closed -$652K
LTRX icon
200
Lantronix
LTRX
$236M
– –
-110,000
Closed -$576K
6 7
8
9 10

Similar funds

SFI
Siemens Fonds Invest Munich, Germany $2.04B AUM 40.78% 1-Year Est. Return
UF
Univest Financial Souderton, Pennsylvania $2.04B AUM 33.06% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
C
Certuity North Palm Beach, Florida $2.03B AUM 88.59% 1-Year Est. Return
EF
Evanson Financial Mclean, Virginia $2.04B AUM
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return

683 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, 683 Capital Management held 257 positions worth $2.04B, up 6.3% from $1.92B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

683 Capital Management withdrew a net $149M in Q2 2026, closing 104 positions and reducing 47 holdings. Its most notable exit was Eli Lilly, an estimated $15.3M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, up from 47% a quarter earlier, followed by Healthcare and Financials.

Against the trend, 683 Capital Management opened a new position in Unity worth $17.6M.

  • 683 Capital Management's largest Q2 2026 buy was Unity: 615,000 shares worth $17.6M.
  • 683 Capital Management added most to Gossamer Bio in Q2 2026, an estimated $9.54M increase.
  • 683 Capital Management's biggest Q2 2026 reduction was Astrana Health, cutting an estimated $17.6M.
  • 683 Capital Management fully exited Eli Lilly in Q2 2026, selling an estimated $15.3M.
  • 683 Capital Management's ten largest holdings make up 47% of its $2.04B portfolio in Q2 2026.
  • 683 Capital Management opened 21 new positions and closed 104 in Q2 2026.
  • 683 Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.04B.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.